Market Synopsis of Global Liquid
Biopsy Market:
Market Scenario:
A liquid biopsy is defined as a
largely non-invasive, sampling and analysis of liquid state biological tissue,
helpful in diagnostic and monitoring diseases such as cancer. Market Research
Future (MRFR) has published a research report about the global liquid biopsy
market that vaticinates immense extension for this market with 28% CAGR
(Compound Annual Growth Rate) between 2015 and 2022. In terms of cash, the
worth of this market has been estimated to be US $ 17,372.28 mn by the end of
forecast period.
The factors contributing to the growth of global liquid
biopsy market include comparatively painless and non-invasive technique, early
real time high precision detection of diseases, effective monitoring, designing
treatment strategies, lifestyle changes, rising investment in research and
development (R&D), collaborations between companies and public organizations,
rise in geriatric population, and rising health expenditure. Other advantages
of liquid biopsy over traditional tissue biopsy include potential applications
to autoimmune diseases, cardiovascular diseases, etc.
The restraints that can harm the market growth during the
forecast period include the prohibitive costs associated with liquid biopsy,
and the differential awareness & availability between developing and the
developed world. Also, early detection does not benefit all cancer patients as
some cancers like brain cancer and prostate cancer may lie dormant for many
years. Lastly, liquid biopsy is not all non-invasive. Use of spinal fluid as
sample proves that.
The global liquid biopsy market has been segmented on the
basis of application, biomarker type, end users, sample, and lastly region.
Based on application, this market has been segmented into cancer therapeutic
application, reproductive health, and other therapeutic application. During the
forecast period, with regards to the therapeutic application, the Cancer
segment will reflect the highest growth potential, with over 82.83% of the
market share by revenues. By biomarker type, the market has been segmented into
circulating tumor cells (CTCS), circulating tumor DNA (CTDNA), extracellular
vesicles (EVS) and other biomarker. Not only CTCS segment dominates the market
share, in terms of revenues, it contributes approx. 55.48% of the revenue share
of the global liquid biopsy market.
On the basis of end users, the market has been segmented
into academic & research centers, hospitals & laboratories, and others.
The sample-based segmentation segments the market into blood, urine and others.
The urine sample segment is expected to witness noticeable growth during the
forecast period.
The regional segmentation of the global liquid biopsy
market segments the market into continent-based regional markets namely The
Americas, Europe, Asia Pacific, and Middle East & Africa (MEA). During the
forecast period, the North America and Europe are expected to grow. The Americas
is the largest regional market due to the availability of advanced medical
technology, and increasing healthcare expenditures, especially in North
America. North America alone holds the potential to be the largest regional
market due to its strong economies that are as the United States of America
(USA) and Canada. Many key market players are based in the USA. In this region,
the availability of advanced medical facilities makes North America a bigger
market than South America.
Europe is the
second largest regional market. After North America, Europe has maximum
technological advancement. The most important country-specific markets in this
region are this region are France, Germany, Italy, Spain, and the United
Kingdom (UK). According to the report, the Asia Pacific region is expected to
emerge as the fastest growing regional market. In this region, the significant
country-specific markets are Australia, China, India, Japan, and South Korea
followed by the rest of Asia Pacific. During the forecast period, the Asia
Pacific market is expected to grow at the 28.8% CAGR.
The MEA region
shows limited market with slow and steady
growth. The reasons for the slow market growth in this region are lack of
awareness, lack of education, lack of technological development, political
instability, poor access to treatment, poor healthcare facilities, and
healthcare not considered a priority by most governments. The crucial country
specific markets in this region are Egypt, Saudi Arabia, and the United Arab
Emirates (UAE).
Key Players
The key players
in the global liquid biopsy
market include Admera Health (USA), Agena Bioscience Inc. (USA), Biocept Inc.
(USA), Circulogene Theranostics (USA), Exosome Diagnostics (USA), Guardant
Health Inc. (USA), Inivata Ltd. (USA), RainDance Technologies Inc. (USA), SAGA
Diagnostics AB (Sweden), and Trovagene Inc. (USA).
Browse Complete 171 Pages Premium Research Report
Enabled with 248 Respective Tables and Figures at @ https://www.marketresearchfuture.com/reports/liquid-biopsy-market-710
TABLE OF CONTENTS
1 Report
Prologue
2
Introduction
2.1
Definition
2.2 Scope Of
The Study
2.2.1
Research Objective
2.2.2
Assumptions
2.2.3
Limitations
2.3 Market
Structure
2.4. Market
Segmentation
3 Research Methodology
3.1 Research
Process
3.2 Primary
Research
3.3 Secondary
Research
5 Market Dynamics
4.1
Drivers
4.2
Restraints
4.3
Opportunities
4.4 Mega
Trends
4.5
Macroeconomic Indicators
5 Market Factor analysis
5.1 Porter’s Five Force Analysis
5.1.1 Bargaining Power Of Buyer
5.1.2 Bargaining Power Of Supplier
5.1.3 Threat From Substitute
5.1.4 Threat From A New Entrant
5.1.5 Intensity Of Competitive Rivalry
...Continued
About
US:
Market Research Future (MRFR), enable customers to unravel
the complexity of various industries through Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed
Research (CFR), and Market Research & Consulting Services.
Contact
Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
No comments:
Post a Comment